For example, some patients treated with the monoclonal antibody fresolimumab have keratoacanthomas, and this adverse effect can be explained by the loss of the inhibitory effects of TGF-β on keratinocyte proliferation [265]. Here, TGFB1 is linked to keratoacanthoma.